Status:

COMPLETED

Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

Lead Sponsor:

Mayo Clinic

Conditions:

Sepsis

Critical Illness

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.

Eligibility Criteria

Inclusion

  • Providers involved with beta-lactam TDM for critically ill patients

Exclusion

  • None

Key Trial Info

Start Date :

October 22 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

138 Patients enrolled

Trial Details

Trial ID

NCT04755777

Start Date

October 22 2020

End Date

December 31 2022

Last Update

February 21 2023

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

UF Health Shands

Gainesville, Florida, United States, 32610

2

Mayo Clinic

Rochester, Minnesota, United States, 55902

3

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia, 4029